Biologics Tied to Lower Eye Risk in Psoriasis - Top-Institutions - MDSpire

Biologics Tied to Lower Eye Risk in Psoriasis

Real-world data suggest lower rates of ocular surface disease with biologics vs nonbiologic systemic therapy.

  • By

  • Andrea Surnit

  • April 20, 2026

  • 2 min

Share

Top Institutions in Dermatology

Brief introduction explaining scope and methodology.

  • #1

    Massachusetts General Hospital
    Massachusetts General Hospital

    Boston, MA

    Key Differentiators

    • Dermatology
    • Ophthalmology
    • Clinical Research

  • #2

    Johns Hopkins University School of Medicine
    Johns Hopkins University School of Medicine

    Baltimore, MD

    Key Differentiators

    • Dermatology
    • Ophthalmology
    • Immunology

  • #3

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Dermatology
    • Ophthalmology
    • Clinical Epidemiology

  • #4

    Hadassah Medical Center
    Hadassah Medical Center

    Jerusalem, Israel

    Key Differentiators

    • Dermatology
    • Ophthalmology
    • Clinical Research

  • #5

    University of California, San Francisco (UCSF)
    University of California, San Francisco (UCSF)

    San Francisco, CA

    Key Differentiators

    • Dermatology
    • Ophthalmology
    • Translational Medicine

Original Source(s)

Biologics Tied to Lower Eye Risk in Psoriasis

  • by Andrea Surnit

  • April 20, 2026

Related Content

Combination Therapy Shows Potential in Psoriasis, Obesity

Researchers assess whether adding tirzepatide to ixekizumab affects skin and weight outcomes in adults with moderate to severe plaque psoriasis.

Development and Validation of the Visual Medical Scale to Evaluate Nail Psoriasis Severity (ViSENPsO®)

Rapid Onset of Action and Quality-of-Life Improvements in Chinese Patients with Plaque Psoriasis Treated with Calcipotriol plus Betamethasone Dipropionate Aerosol Foam in a Randomized Phase 3 Trial